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ABSTRACT
Asthma and chronic obstructive pulmonary disease (COPD) are 
the two most prevalent obstructive diseases of the lung. Although 
asthma and COPD differ in many ways some properties of each 
disease co-exist in some patients, particularly in patients with 
advanced age which recently brought up the term; Asthma-COPD 
Overlap Syndrome (ACOS). In addition to the fact that clinical 
trials deliberately exclude the patients in this group, the diagnostic 
criteria of ACOS are not well established. Both of these factors 
contribute to paucity of evidence based clinical information about 
ACOS. In this article my aim is to provide brief information about 
the history, description, clinical properties and treatment of this 
disease.
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Introduction
Asthma and COPD are two highly prevalent forms of 
obstructive lung diseases, which lead to significant utilization 
of the healthcare systems worldwide. The hypothesis which 
proposes asthma and COPD to use common pathogenic 
mechanisms is referred as the ‘’Dutch Hypothesis’’ and was 
first introduced in 1960 by N. G. M Orie and H. J. Sluiter in a 
multidisciplinary symposium in Groningen where scientists 
noted that clinical expressions of the disease are determined 
by endogenous (i.e. genetic factors, age, sex) and exogenous 
(i.e. environmental such as allergens, smoking, viruses) 
factors. In the following years opinions for and against this 
hypothesis were expressed and a ‘’British Theory’’ was 
formed which states asthma and COPD are two distinct 
entities with different pathogenesis [1].
The guidelines that direct our clinical practice have been 
highlighting the importance of correctly identifying these 
two diseases in order to treat and manage properly. 
Definition and diagnosis of ACOS
Of these two diseases which are characterized by chronic 
airway inflammation, asthma is known to have a usually 
reversible inflammatory process which is dominated by 
Th2 cytokines, CD4+ lymphocytes or eosinophils and 
typically responds well to inhaled corticosteroids (ICS). 
Symptoms and signs are intermittent and may sometimes 
remit completely. However, in COPD inflammation is 
mainly mediated by Th1 cytokines with abundant CD8+ 
lymphocytes or neutrophils, signs and symptoms related 
to airway obstruction are progressive. In our daily practice 
we frequently observe patients with signs and symptoms of 
each disease which brought up the term ‘ACOS’ first time 
in 2007 in the Canadian Thoracic Society COPD guideline 
where it was recommended to treat COPD patients with 
prominent asthma component differently by adding ICS 
earlier in the course of treatment [2]. During recent years 
attention devoted to ACOS increased substantially and 
descriptions regarding ACOS were introduced both from 
asthma and COPD perspectives. ACOS diagnostic criteria 
(Table I) defined by Spanish experts in 2012 was later on 
incorporated into their consensus statement on ACOS and 
COPD Spanish guideline (GesEPOC) [3, 4]. Meanwhile 
some other European countries’ guidelines mentioned 
similar ACOS criteria as well [5]. Many of these included 
variables, which are neither used in daily practice nor 
available in many centers and mainly based on expert 
opinions. Many epidemiologic studies suggested the main 
feature of ACOS should be diagnosis of asthma before the 
age of 40 in a patient with COPD however this suggestion 
did not gain traction thus not widely accepted [6].
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Table I. ACOS criteria proposed by Spanish Thoracic Society
Major Minor 
1.Very positive 
bronchodilator test  
(increase in FEV1% ≥15% 
and ≥400ml over baseline)
1.High total IgE 
2.Eosinophilia in sputum 2.Personal history of atopy 
3.Personal history of 
asthma (before the age 
of 40)
3.Positive bronchodilator test  
(increase in FEV1% ≥12% and 
≥200ml over baseline) on 2 or 
more occasions 
Two major criteria, or 1 major and  2 minor criteria are necessary 
for diagnosis.
In 2014 Global Initiative for Asthma (GINA) and Global 
Initiative for Chronic Obstructive Lung Diseases (GOLD) 
scientific committees issued a joint statement describing 
ACOS as a syndrome characterized by persistent airflow 
limitation with several features usually associated with 
asthma and several features usually associated with COPD. 
This overlap makes differentiation of asthma and COPD 
difficult particularly in smokers with advanced age who have 
persistent airway obstruction. In order to serve this purpose 
essential properties of the diseases are listed followed 
by a separate table which identifies how many of those 
are possessed by the patient and which diagnosis is more 
favorable over the other (Tables II and III). It is suggested 
to consider either asthma or COPD if three or more of the 
disease properties listed in Table III are present or to consider 
the diagnosis of ACOS if patients possess similar numbers 
of properties of asthma or COPD [7, 8].
Furthermore, besides patients’ history, physical 
examination and imaging studies findings it is suggested to 
use pulmonary function testing parameters to support the 
diagnosis. Pulmonary function testing parameters in asthma, 
COPD and ACOS are listed in Table IV  [7, 8]. 
In the light of the aforementioned knowledge ACOS is 
practically defined as COPD patients with high reversibility 
and/or asthma patients with advanced age who do not exhibit 
completely reversible airway obstruction [9].
Table II. Usual features of asthma, COPD and ACOS
Feature  Asthma COPD ACOS 
Age of onset Usually childhood onset but can 
commence at any age
Usually > 40 years of age Usually age ≥40 years, but may have had 
symptoms in childhood or early adulthood
Pattern of
respiratory
symptoms
Symptoms may vary over time 
(day to day, or over longer 
periods), often limiting activity. 
Often triggered by exercise, 
emotions including laughter, 
dust or exposure to allergens
Chronic usually continuous 
symptoms, particularly during 
exercise, with ‘better’ and 
‘worse’ days
Respiratory symptoms including 
exertional dyspnea are persistent but 
variability may be prominent
Lung function Current and/or historical
variable airflow limitation,  e.g. 
BD reversibility, AHR
FEV1 may be improved by 
therapy, but post-BD FEV1/FVC 
< 0.7 persists
Airflow limitation not fully reversible, but 
often with current or historical variability
Lung function 
between symptoms 
May be normal between symptoms Persistent airflow limitation Persistent airflow limitation
Past history or 
family history
Many patients have
allergies and a personal
history of asthma in childhood, 
and/or family history of asthma
History of exposure to
noxious particles and gases 
(mainly tobacco smoking and 
biomass fuels)
Frequently a history of doctor diagnosed 
asthma (current or
previous), allergies and a family history 
of asthma, and/or a history of noxious 
exposures
Time course Often improves spontaneously 
or with treatment, but may result 
in fixed airflow limitation
Generally, slowly progressive 
over years despite treatment
Symptoms are partly but significantly 
reduced by treatment. Progression is usual 
and treatment needs are high
Chest X-ray Usually normal Severe hyperinflation &other 
changes of COPD
Similar to COPD 
Exacerbations Exacerbations occur, but the 
risk of exacerbations can 
be considerably reduced by 
treatment
Exacerbations can be
reduced by treatment. If present, 
comorbidities
contribute to impairment
Exacerbations may be more common 
than in COPD but are reduced by 
treatment. Comorbidities can contribute to 
impairment
Airway 
inflammation
Eosinophils and/or neutrophils Neutrophils ± eosinophils in 
sputum, lymphocytes in airways, 
may have systemic inflammation
Eosinophils and/or neutrophils in sputum.
BD=bronchodilator, AHR=airway hyperresponsiveness
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Table III. Features which favor asthma or COPD if present
Feature More likely to be asthma
if several of *
More likely to be COPD
if several of *
Age of onset •  Onset before age 20 years • Onset after age 40 years
Pattern of
respiratory
symptoms
• Variation in symptoms over minutes, hours 
or days
• Symptoms worse during the night or early 
morning
• Symptoms triggered by exercise, emotions 
including laughter, dust or exposure to 
allergens
• Persistence of symptoms despite 
treatment
• Good and bad days but always daily 
symptoms and exertional dyspnea
• Chronic cough and sputum preceded 
onset of dyspnea, unrelated to triggers
Lung function • Record of variable airflow limitation 
(spirometry, peakflow)
• Record of persistent airflow limitation 
(post-BD
• FEV1/FVC < 0.7)
Lung function between symptoms • Lung function normal between symptoms • Lung function abnormal between 
symptoms
Past history or family history • Previous doctor diagnosis of asthma
• Family history of asthma, and other allergic 
conditions (allergic rhinitis or eczema)
• Previous doctor diagnosis of COPD, 
chronic bronchitis or emphysema
• Heavy exposure to a risk factor: tobacco 
smoke, biomass fuels
Time course • No worsening of symptoms over time. 
Symptoms vary either seasonally, or from 
year to year
• May improve spontaneously or have an 
immediate response to BD or to ICS over 
weeks
• Symptoms slowly worsening over time 
(progressive course over years)
• Rapid-acting BD 
       treatment provides only limited relief
Chest X-ray •  Normal • Severe hyperinflation
BD=bronchodilator, ICS=inhaled corticosteroids
Table IV. Spirometric measures in asthma, COPD and ACOS
Spirometric variable Asthma COPD ACOS
Normal FEV1 /FVC
pre- or post BD
Compatible with diagnosis Not compatible with diagnosis Not compatible unless other 
evidence of chronic airflow 
limitation
Post-BD FEV1 /FVC <0.7 Indicates airflow limitation 
but may improve 
spontaneously or on treatment
Required for diagnosis (GOLD) Usually present
FEV1 ≥80% predicted Compatible with diagnosis 
(good asthma control or
interval between symptoms)
Compatible with GOLD 
classification of mild airflow 
limitation (categories A or B) if 
post-BD FEV1 /FVC <0.7
Compatible with diagnosis of 
mild ACOS
FEV1  <80% predicted Compatible with diagnosis 
Risk factor for asthma
exacerbations
An indicator of severity of 
airflow limitation and risk of 
future events (e.g. mortality
and COPD  exacerbations)
An indicator of severity of 
airflow limitation and risk of 
future events (e.g. mortality
and exacerbations)
Post-BD increase in FEV1  
≥12% and 200 ml from 
baseline (reversible airflow
limitation)
Usual at some time in course 
of asthma, but may not be 
present when well-controlled 
or on controllers
Common and more likely when 
FEV1 is low
Common and more likely when 
FEV1 is low
Post-BD increase in 
FEV1>12% and 400ml from 
baseline (marked
reversibility)
High probability of asthma Unusual in COPD. Consider 
ACOS
Compatible with diagnosis of 
ACOS
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Epidemiology
Based on the diagnostic criteria of many published studies 
ACOS prevalence varies from 5 to 55%. Marco et al. from 
Italy reported ACOS prevalence as 1.6% in 20-44 year olds, 
2.1% in 45-64 year olds and 4.5% in 65-84 year olds [10].
Investigations, which focus on databases of COPD studies 
and quantify the COPD patients who have documented 
doctor diagnosed asthma reached a quite high ACOS 
prevalence. Hardin et al. in their COPDGene study reported 
a prevalence of 13%. In their EPI-SCAN study Miravitlles 
et al. similarly reported that 17.4% of COPD patients have 
prior physician documented diagnosis of asthma [6]. A study 
from Barcelona, Spain reported prevalence of ACOS as 
15.9% [5]. Another study by Soriano et al. noted that ACOS 
prevalence increases with age. It is 10% under 50 years 
olds however over 50% in patients who are over 50 years 
old [11]. Menezes and Hardin reported higher mean age in 
ACOS patients [12, 13]. Increase of prevalence with aging 
is thought to be related to the development of persistent 
airway obstruction due to inadequate treatment or ongoing 
insults such as smoking [14, 15]. A study by Kiljander et 
al. revealed ACOS prevalence as 27.4% in asthma patients 
who have a history of smoking. Smoking 20 pack years and 
age over 60 years were best predictors of ACOS in the study 
population  and these risk factors together increase ACOS 
risk 6 fold (p: 0.001) [16]. The reason suggested to explain 
high ACOS prevalence is that asthma and airway hyper-
responsiveness to be among the COPD risk factors. Lange 
et al. identified that deterioration of pulmonary functions is 
more rapid in asthma patients with even more prominence 
in smokers [17]. Another study revealed that 16% of asthma 
patients developed irreversible airway obstruction over a 
follow up period of 26 years [15].
Clinical properties
Although studies on ACOS are increasing in number, 
information regarding clinical properties of the disease is 
limited. 
Brzostek and Kokot’s study from Poland reported 68% 
of patients complained of dyspnea on exertion, 63% had 
wheezing and paroxysmal nocturnal dyspnea and 72% had 
chronic productive cough [18].
EPI-SCAN study of Miravitlles et al. revealed that 
when compared to COPD patients, ACOS patients had 
more dyspnea (p<0.001) and wheezing (92.5% vs 58.2%, 
p<0.001) but there were no differences between these two 
groups in terms of cough and sputum production. 6-minute 
walking test results between two groups were not different 
either [6].
On the contrary, Menezes et al. described ACOS patients 
as the patient group who complained of cough and sputum 
production most frequently (p<0.001). This study revealed 
dyspnea symptom is more frequent in asthma patients 
whereas in terms of wheezing, asthma and ACOS patients 
have similar frequency, which is significantly more than 
COPD patients [12]. 
de Marco  et al. reported  that  when compared to COPD 
patients, ACOS patients had higher modified Medical 
Research Council (mMRC) scores, had more dyspnea, cough, 
sputum production and wheezing. Furthermore, ACOS 
patients had more frequent symptoms, more prominent 
physical impairment and higher number of hospital 
admissions [10]. Another population based cohort study of de 
Marco with a different group of investigators revealed when 
compared to asthma and COPD patients ACOS patients had 
worse basal pulmonary functions and their decline in FEV1 
and FVC was similar to asthma patients but less than COPD 
patients. Additionally, respiratory problems necessitating 
emergency or hospital admissions were found to be twice 
as often in ACOS patients than COPD and asthma patients 
[19]. Two studies, which investigated pulmonary function 
parameters, revealed worse results in ACOS patients [6, 
12] whereas Kauppi et al. and Fabbri et al. reported better 
parameters in ACOS patients [20, 21]. However, it should be 
noted that in none of these studies these differences reached 
statistical significance.
In terms of exacerbation history studies by Hardin et 
al., Miravitlles et al. and Menezes et al. revealed that when 
compared to COPD patients ACOS patients have more 
frequent exacerbations [6, 12, 13].
Serious exacerbations necessitating inpatient care are 
found to be more frequent in ACOS patients when compared 
to patients with COPD [10, 12, 13].
A study performed in South Korea revealed more 
significant airway obstruction (i.e. low FEV1/FVC and low 
FEV1% predicted), more frequent hospital admissions due 
to respiratory problems and higher mortality rates [22].
On the contrary, there are conflicting reports as well. A 
study from Australia concluded that when compared to ACOS 
patients COPD patients have worse prognosis, worse physical 
performances and more prominent decline in pulmonary 
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functions. Additionally, COPD patients had higher rates of 
mortality than asthma and ACOS patients [23].
Another report from Japan stated COPD patients had 
higher rates of mortality when compared to asthma and 
ACOS patients. Also, length of hospital stay, intensive care 
unit stay  and duration of mechanical ventilation were longer 
in COPD patients [24].
CHAIN study, which was performed in Spain on a cohort 
of COPD patients, ACOS patients were found to have better 
1-year survival rates with no significant difference in terms 
of exacerbation frequency [25].
Inflammation and Biomarkers
Data regarding ACOS patients and systemic inflammation are 
pretty limited. Available knowledge is widely extrapolated 
from previous asthma and COPD studies. In contrast to the 
eosinophilic inflammation, which is commonly observed 
in asthma patients, a non-eosinophilic asthma group is 
identified with predominant neutrophilic inflammation 
whose steroid response is poor. Meanwhile it is revealed 
that asthma patients who had persistent airway obstruction 
mainly suffered from neutrophilic inflammation [26].
Similarly, in COPD patients who are mainly affected 
by neutrophilic inflammation some patients have higher 
numbers of eosinophils in serum and sputum samples. These 
patients respond well to ICS, particularly who have high 
numbers of eosinophils in induced sputum [27].
According to the data we can reach to the conclusion that 
inflammation in asthma and COPD have different properties 
and some patients carry similarities to each of the groups 
which support the diagnosis of ACOS [28].
In 2014 Chinese investigators studied systemic 
inflammation in ACOS patients and checked their 
C-reactive protein (CRP) and interleukin-6 (IL-6) levels to 
compare with the available data from COPD and asthma 
patients, which are readily available. Study revealed that 
CRP and IL-6 levels in ACOS patients were higher than 
asthma patients and similar to COPD patients suggesting 
that ongoing systemic inflammation in ACOS patients is as 
worse as COPD patients [29].
Treatment
Studies regarding obstructive lung diseases generally exclude 
asthma patients when investigating COPD treatment options 
and the opposite is true as well. Therefore, our knowledge 
on ACOS treatment generally relies on treatment strategies 
mentioned in asthma and COPD guidelines. Treatment trials 
performed solely on ACOS patients are pretty limited. The 
aims of ACOS treatment are controlling the symptoms and 
decreasing the impairment while eliminating the risks of 
pulmonary function deterioration, exacerbations and side 
effects of medications. While main reasons of morbidity in 
ACOS are cough, sputum production, wheezing, dyspnea 
on exertion, physical deconditioning and medication side 
effects, mortality is primarily related to exacerbations 
resulting in respiratory failure. Main principles of treatment 
are achieving symptom control cost-effectively, decreasing 
the number of exacerbations without any major side effects, 
improving quantifiable functional parameters and improving 
quality of life [30].
Canadian Thoracic Society guideline published in 
2007 contains information regarding ACOS patients and 
recommends long acting beta agonists (LABA) and long 
acting muscarinic receptor antagonists (LAMA) as primary 
choice of treatment while considering ICS treatment earlier 
in the course of patients with prominent asthma component. 
Meanwhile it is recommended to set different goals of 
treatment when compared to asthma and COPD patients 
with particular emphasis on patient education and self 
management plans [2].
Czech Pneumological and Phthisiological Society’s 
COPD guideline recommends ICS + LABA combination 
as first line of treatment with proven efficacy while 
recommending ICS + LABA + LAMA combination as an 
alternative. Lastly, adjunct anti-leucotriene treatments are 
recommended as complementary [31]. 
A consensus statement from Spain in 2012 recommends 
ICS early in the course of treatment of every patient to 
suppress inflammation and using symptoms, pulmonary 
functions and/or sputum eosinophilia for titrating the 
dose of ICS. Due to the natural properties of COPD, it 
is recommended to add long acting bronchodilators to 
ICS and even consider triple therapy of ICS, LABA and 
LAMA if symptom control is not achieved. Even though 
there are conflicting statements in the consensus, early 
discontinuation of ICS is not recommended since this may 
trigger exacerbations [3].
Spanish COPD guideline published later in 2014 includes 
a section dedicated to ACOS patients’ management where 
addition of theophylline to treatment in advanced cases and 
a phosphodiesterase inhibitor roflumilast in patients with 
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chronic bronchitis phenotype is recommended [4].
GINA and GOLD guidelines include joint 
recommendations on ACOS treatment which include 
ICS + LABA or ICS + LAMA or ICS + LABA + LAMA 
combinations. Additionally, they explicitly express which 
patients should be referred to experienced centers or drug 
trials. Patients who have persistent symptoms despite 
treatment, who have exacerbations, whose diagnosis is 
uncertain, who have additional symptoms such as hemoptysis, 
weight loss, night sweats, fever and bronchiectasis signs, who 
have comorbidities should be referred to more experienced 
centers. Meanwhile all patients should receive treatment 
and recommendations about their modifiable risk factors 
including smoking cessation, management of comorbidities, 
non-pharmacological treatments such as physical activities, 
pulmonary rehabilitation and vaccination and proper self 
management strategies and regular follow-up [7, 8].
Two case series comprising of 10 and 3 ACOS patients 
reported good response to omalizumab treatment while 
mentioning the necessity of further studies [32, 33].
Conclusion
ACOS should be kept in mind in patients who have prior 
diagnosis of asthma or COPD while possessing properties of 
each disease. To establish internationally accepted diagnostic 
criteria and determine treatment strategies, more studies 
including this specific group of patients are necessary. Our 
current knowledge relies on applying the proper treatment 
recommended by asthma and COPD guidelines according 
to the clinical properties of patients. If there is doubt about 
diagnosis or treatment, patients should be referred to 
experienced centers.
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